Abstract: The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFN?5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFN?5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.
Abstract: 5?-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (MS), as well as in the prevention and/or treatment of transplant rejection.
Type:
Application
Filed:
March 17, 2005
Publication date:
February 12, 2009
Applicant:
Proyecto de Biomedicina Cima, S.L.
Inventors:
Pablo Villoslada Diaz, Matias Avila Zaragoza, Beatriz Moreno Bruna, Fernando Corrales Izquierdo, Carmen Berasain Lasarte, Elena Ruiz Garcia-Trevijano
Abstract: The present invention relates to methods for predicting sensitivity and response to a chemotherapy in a patient suffering from breast cancer based on the detection of the presence or absence of a deletion in the human chromosome region 11q21-q25 in a breast tumor sample from said patient.
Type:
Application
Filed:
May 12, 2006
Publication date:
November 15, 2007
Applicants:
PROYECTO DE BIOMEDICINA CIMA, S.L., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Joan Climent-Bataller, Jose Martinez-Climent, Daniel Pinkel, Donna Albertson
Abstract: Antagonistic synthetic peptides, obtained from TGF?1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.
Type:
Grant
Filed:
November 23, 1999
Date of Patent:
June 6, 2006
Assignee:
Proyecto de Biomedicina Cima, S.L.
Inventors:
Ignacio José Ezquerro Saenz, Juan José Lasarte Sagastibelza, Jesús Prieto Valtue{overscore (n)}a, Francisco Borras Cuesta
Abstract: The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFN?5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFN?5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.